Lilly Gets Second Interchangeable Insulin Glargine In US
Further FDA Approval For Rezvoglar Biosimilar Adds Second Interchangeable Option
Eli Lilly has been granted an interchangeability designation by the US FDA for its Rezvoglar insulin glargine biosimilar, matching the designation previously granted for Viatris’ Semglee.
